Cargando…

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)

BACKGROUND: Few studies have exclusively investigated the value of pathological complete response (pCR), in esophageal squamous cell carcinoma (ESCC) patients, although it is a clinically significant parameter to evaluate the impact of neoadjuvant chemoradiotherapy (nCRT) on treatment outcome after...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jianfei, Kong, Min, Yang, Hong, Jin, Ke, Chen, Yuping, Fang, Wentao, Yu, Zhentao, Mao, Weimin, Xiang, Jiaqing, Han, Yongtao, Chen, Zhijian, Yang, Haihua, Wang, Jiaming, Pang, Qingsong, Zheng, Xiao, Yang, Huanjun, Li, Tao, Zhang, Xu, Li, Qun, Wang, Geng, Mao, Teng, Guo, Xufeng, Lin, Ting, Liu, Mengzhong, Ma, Dehua, Ye, Minhua, Wang, Chunguo, Wang, Zheng, Brunelli, Alessandro, Cerfolio, Robert J., D’Journo, Xavier Benoit, Fernando, Hiran C., Lordick, Florian, Fu, Jianhua, Chen, Baofu, Zhu, Chengchu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576689/
https://www.ncbi.nlm.nih.gov/pubmed/34790722
http://dx.doi.org/10.21037/atm-21-3331
_version_ 1784595927877550080
author Shen, Jianfei
Kong, Min
Yang, Hong
Jin, Ke
Chen, Yuping
Fang, Wentao
Yu, Zhentao
Mao, Weimin
Xiang, Jiaqing
Han, Yongtao
Chen, Zhijian
Yang, Haihua
Wang, Jiaming
Pang, Qingsong
Zheng, Xiao
Yang, Huanjun
Li, Tao
Zhang, Xu
Li, Qun
Wang, Geng
Mao, Teng
Guo, Xufeng
Lin, Ting
Liu, Mengzhong
Ma, Dehua
Ye, Minhua
Wang, Chunguo
Wang, Zheng
Brunelli, Alessandro
Cerfolio, Robert J.
D’Journo, Xavier Benoit
Fernando, Hiran C.
Lordick, Florian
Fu, Jianhua
Chen, Baofu
Zhu, Chengchu
author_facet Shen, Jianfei
Kong, Min
Yang, Hong
Jin, Ke
Chen, Yuping
Fang, Wentao
Yu, Zhentao
Mao, Weimin
Xiang, Jiaqing
Han, Yongtao
Chen, Zhijian
Yang, Haihua
Wang, Jiaming
Pang, Qingsong
Zheng, Xiao
Yang, Huanjun
Li, Tao
Zhang, Xu
Li, Qun
Wang, Geng
Mao, Teng
Guo, Xufeng
Lin, Ting
Liu, Mengzhong
Ma, Dehua
Ye, Minhua
Wang, Chunguo
Wang, Zheng
Brunelli, Alessandro
Cerfolio, Robert J.
D’Journo, Xavier Benoit
Fernando, Hiran C.
Lordick, Florian
Fu, Jianhua
Chen, Baofu
Zhu, Chengchu
author_sort Shen, Jianfei
collection PubMed
description BACKGROUND: Few studies have exclusively investigated the value of pathological complete response (pCR), in esophageal squamous cell carcinoma (ESCC) patients, although it is a clinically significant parameter to evaluate the impact of neoadjuvant chemoradiotherapy (nCRT) on treatment outcome after surgery. The aim of our study was to explore the relationship between pCR after nCRT and survival among patients with local ESCC. METHODS: All patients receiving nCRT followed by surgery in NEOCRTEC5010-trial (NCT01216527) were included. Non-pCR patients were classified into three subgroups: ypTanyN0M0, ypT0NanyM0 and ypTanyNanyM0. The Kaplan-Meier method with log-rank test was employed to evaluate disease-free survival (DFS) and overall survival (OS). Multivariate regression analysis was performed using a Cox proportional hazards model to identify clinicopathological parameters associated with pCR. RESULTS: Among the 185 patients included, 80 (43.2%) achieved pCR after nCRT. The mean survival time of the pCR group was significantly longer than that of the non-pCR group (92.6 vs. 69.2 months; HR, 2.70; 95% CI: 1.48–4.92; P=0.001). The 5-year OS and DFS of the pCR group were 79.3% and 77% respectively, compared to 54.8% and 51.2%, respectively, in the non-pCR group. The results showed that the OS and DFS of the ypTanyN0M0 group were better than those of the ypT0NanyM0 group and the ypTanyNanyM0 group. We also found that the number of dissected lymph nodes and pCR were independent risk factors for DFS and OS rates. CONCLUSIONS: pCR after nCRT is an important prognostic indicator of OS and DFS in patients with ESCC. In addition, lymph-node status could represent an important parameter in the prognostic evaluation of esophageal cancer patients.
format Online
Article
Text
id pubmed-8576689
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85766892021-11-16 Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010) Shen, Jianfei Kong, Min Yang, Hong Jin, Ke Chen, Yuping Fang, Wentao Yu, Zhentao Mao, Weimin Xiang, Jiaqing Han, Yongtao Chen, Zhijian Yang, Haihua Wang, Jiaming Pang, Qingsong Zheng, Xiao Yang, Huanjun Li, Tao Zhang, Xu Li, Qun Wang, Geng Mao, Teng Guo, Xufeng Lin, Ting Liu, Mengzhong Ma, Dehua Ye, Minhua Wang, Chunguo Wang, Zheng Brunelli, Alessandro Cerfolio, Robert J. D’Journo, Xavier Benoit Fernando, Hiran C. Lordick, Florian Fu, Jianhua Chen, Baofu Zhu, Chengchu Ann Transl Med Original Article BACKGROUND: Few studies have exclusively investigated the value of pathological complete response (pCR), in esophageal squamous cell carcinoma (ESCC) patients, although it is a clinically significant parameter to evaluate the impact of neoadjuvant chemoradiotherapy (nCRT) on treatment outcome after surgery. The aim of our study was to explore the relationship between pCR after nCRT and survival among patients with local ESCC. METHODS: All patients receiving nCRT followed by surgery in NEOCRTEC5010-trial (NCT01216527) were included. Non-pCR patients were classified into three subgroups: ypTanyN0M0, ypT0NanyM0 and ypTanyNanyM0. The Kaplan-Meier method with log-rank test was employed to evaluate disease-free survival (DFS) and overall survival (OS). Multivariate regression analysis was performed using a Cox proportional hazards model to identify clinicopathological parameters associated with pCR. RESULTS: Among the 185 patients included, 80 (43.2%) achieved pCR after nCRT. The mean survival time of the pCR group was significantly longer than that of the non-pCR group (92.6 vs. 69.2 months; HR, 2.70; 95% CI: 1.48–4.92; P=0.001). The 5-year OS and DFS of the pCR group were 79.3% and 77% respectively, compared to 54.8% and 51.2%, respectively, in the non-pCR group. The results showed that the OS and DFS of the ypTanyN0M0 group were better than those of the ypT0NanyM0 group and the ypTanyNanyM0 group. We also found that the number of dissected lymph nodes and pCR were independent risk factors for DFS and OS rates. CONCLUSIONS: pCR after nCRT is an important prognostic indicator of OS and DFS in patients with ESCC. In addition, lymph-node status could represent an important parameter in the prognostic evaluation of esophageal cancer patients. AME Publishing Company 2021-10 /pmc/articles/PMC8576689/ /pubmed/34790722 http://dx.doi.org/10.21037/atm-21-3331 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Shen, Jianfei
Kong, Min
Yang, Hong
Jin, Ke
Chen, Yuping
Fang, Wentao
Yu, Zhentao
Mao, Weimin
Xiang, Jiaqing
Han, Yongtao
Chen, Zhijian
Yang, Haihua
Wang, Jiaming
Pang, Qingsong
Zheng, Xiao
Yang, Huanjun
Li, Tao
Zhang, Xu
Li, Qun
Wang, Geng
Mao, Teng
Guo, Xufeng
Lin, Ting
Liu, Mengzhong
Ma, Dehua
Ye, Minhua
Wang, Chunguo
Wang, Zheng
Brunelli, Alessandro
Cerfolio, Robert J.
D’Journo, Xavier Benoit
Fernando, Hiran C.
Lordick, Florian
Fu, Jianhua
Chen, Baofu
Zhu, Chengchu
Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title_full Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title_fullStr Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title_full_unstemmed Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title_short Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
title_sort pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (neocrtec5010)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576689/
https://www.ncbi.nlm.nih.gov/pubmed/34790722
http://dx.doi.org/10.21037/atm-21-3331
work_keys_str_mv AT shenjianfei pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT kongmin pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT yanghong pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT jinke pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT chenyuping pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT fangwentao pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT yuzhentao pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT maoweimin pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT xiangjiaqing pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT hanyongtao pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT chenzhijian pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT yanghaihua pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT wangjiaming pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT pangqingsong pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT zhengxiao pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT yanghuanjun pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT litao pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT zhangxu pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT liqun pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT wanggeng pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT maoteng pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT guoxufeng pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT linting pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT liumengzhong pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT madehua pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT yeminhua pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT wangchunguo pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT wangzheng pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT brunellialessandro pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT cerfoliorobertj pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT djournoxavierbenoit pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT fernandohiranc pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT lordickflorian pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT fujianhua pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT chenbaofu pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT zhuchengchu pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010
AT pathologicalcompleteresponseafterneoadjuvanttreatmentdeterminessurvivalinesophagealsquamouscellcarcinomapatientsneocrtec5010